Better Health for All

Amicus Therapeutics' core business is developing and delivering transformative medicines for rare diseases like Fabry and Pompe, which cause progressive organ damage and muscle weakness.

Its entire portfolio is dedicated to these conditions, delivering innovative medicines to over 3,400 patients worldwide as of December 2025, indicating a revolutionary health benefit. The company offers patient assistance programs (PAPs) providing free or low-cost drugs to eligible uninsured/underinsured patients and co-pay assistance for commercially insured patients. It also focuses on rare disease communities and supports patients in state/federally funded programs, aiming to reach those unable to pay for medication. However, no specific data on the percentage of vulnerable populations reached is provided. The company states it provides comprehensive risk summaries in its annual report, commits to truthful product information, and publishes disclosure data for multiple countries, including important safety information for its products. Despite this, it also explicitly states that its products or product candidates may have side effects that could impact regulatory approval or commercialization, and that employees, independent contractors, principal investigators, consultants, and vendors may engage in misconduct or improper activities which could lead to significant liability and harm its reputation. Amicus is leveraging global capabilities to develop next-generation therapies and novel technologies for Fabry and Pompe disease, and entered a license agreement with Penn for pre-clinical research and development of gene therapy products for these diseases, demonstrating a revolutionary investment in health innovation. The company's activities are subject to various federal and state fraud and abuse laws, including HIPAA, which imposes obligations on safeguarding patient data privacy and security. However, the company also states that its employees, independent contractors, principal investigators, consultants, and vendors may engage in misconduct or improper activities which could lead to significant liability and harm its reputation. Clinical trials must comply with government regulations and Good Clinical Practice, and protocols must be approved by an Institutional Review Board. The FDA usually recommends observing subjects for potential gene therapy-related delayed adverse events for a 15-year period. However, the company also states that its employees, independent contractors, principal investigators, consultants, and vendors may engage in misconduct or improper activities which could lead to significant liability and harm its reputation.

Fair Money & Economic Opportunity

Amicus Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapies for rare diseases. Its core business activities, as evidenced by the articles, involve medication development, patent litigation,

and patient support programs for accessing medication. The company does not offer lending, insurance, deposit, or other consumer financial services. Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to its operations.

Fair Pay & Worker Respect

For 2024, the CEO-to-median employee pay ratio was 33:1, with the CEO's compensation at $8,526,943 and the median employee's at $259,999.

Employee feedback indicates that 77% of employees would recommend working at the company. The overall employee rating is 3.6 out of 5 stars, and 82% of employees approve of the CEO. There is no information provided regarding any regulatory actions, violations, fines, or compliance issues.

Honest & Fair Business

Amicus Therapeutics has an EthicsPoint hotline for confidential and anonymous reporting of concerns, and the company states it investigates all reports and prohibits retaliation against those who report in good faith.

The company has not had any formal financial restatements recently, only minor disclosure tweaks, and its annual, quarterly, and current reports are available on its website. As of 2016, 75% of the board members were determined to be independent. The company has a comprehensive anti-corruption policy, with 100% of employees receiving annual training on the Global Code of Conduct, data protection cybersecurity, social media, and a global anti-bribery/corruption policy. However, the policy lacks customization for high-risk areas.

Kind to Animals

Amicus Therapeutics, Inc. (FOLD.US) conducts animal studies as a standard part of its preclinical and Investigational New Drug (IND) phase development, including long-term safety evaluations for reproductive toxicity and carcinogenicity.

The company is noted to have 'Significant Involvement' in animal testing. While compliance with Good Laboratory Practice (GLP) for preclinical tests is mentioned, there is no explicit formal policy to reduce or restrict animal testing, nor any stated commitment to phasing out or replacing these tests with non-animal alternatives. The company's practice indicates routine animal testing continues without a publicly disclosed policy for reduction or restriction.

No War, No Weapons

Amicus Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapies for rare diseases, with its primary revenue derived from pharmaceutical products like Galafold and Pombiliti + Opfolda.

The provided articles contain no evidence of the company's involvement in arms manufacturing, military contracts, dual-use technology, sales to embargoed regimes, or any other activities related to the 'No War, No Weapons' value. The company's corporate giving and financial support are directed towards healthcare-related organizations and patient communities. Therefore, all KPIs related to defense, arms, or conflict are scored as N/A, indicating no applicable activities in these areas.

Planet-Friendly Business

Amicus Therapeutics joined the CDP Supply Chain Program to improve environmental information across its supply chain.

However, no specific data is provided regarding the percentage of suppliers disclosing emissions or the depth of this disclosure (e.g., Tier 1-3 coverage). Without this quantitative detail, joining the program indicates an intent but does not meet the thresholds for higher scores, placing it at the lowest available tier for engagement without specific disclosure metrics.

Respect for Cultures & Communities

No specific, quantifiable evidence was found across the provided articles to assess Amicus Therapeutics, Inc. against the defined KPIs for 'Respect for Cultures & Communities'. The articles mention general charitable giving programs

and employee training on a Global Code of Conduct, but lack concrete data points regarding formal partnerships with indigenous or local community groups, revenue reinvested in local community development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, community-specific grievance mechanisms, complaint resolution times, FPIC participation, community governance inclusion, cultural preservation investment, local procurement, indigenous suppliers, cultural site protection, social license to operate, charitable giving to cultural heritage organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion rates.

Safe & Smart Tech

The company reports no specific data breach incidents or unauthorized data use.

It has certified its adherence to the EU-U.S., Swiss-U.S., and UK extensions to the EU-U.S. Data Privacy Framework Principles with the U.S. Department of Commerce. Amicus Therapeutics provides regular, mandatory cybersecurity training for all personnel. The company states it integrates with NIST and other industry standards, performs vulnerability assessments, cybersecurity threat intelligence, audits, tabletop exercises, threat modeling, and vulnerability testing. Technical safeguards, including access controls and authentication methods, are deployed.

Zero Waste & Sustainable Products

No specific, concrete data points were found in the provided articles for any of the KPIs related to Zero Waste & Sustainable Products. The articles discuss general ESG reporting and packaging design focused on patient compliance.

but do not provide metrics on waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.